title: Perphenazine suspension: a new, old treatment, side effects and continuous use.
abstract: A number of innovative delivery systems for acute antipsychotic pharmacotherapy have been developed over the years which include oral suspensions, rapidly dissolving wafers and acute intramuscular preparations. Currently, the availability of first generation antipsychotic (FGA) formulations is limited to two high potency agents: haloperidol and fluphenazine. At Yale New-Haven Psychiatric Hospital, the hospital pharmacy was able to create perphenazine suspension, a mid-potency FGA, with a record of effectiveness and tolerability that was no worse than that of second generation antipsychotics (SGAs) in the CATIE trial. In this study we compare perphenazine suspension to other first and SGAs in the risk of extrapyramidal reactions and whether or not patients were continued on the same antipsychotic they were started with at the time of discharge. Medical records of patients who received acute pharmacotherapy in a unique form while hospitalized at Yale New Haven Psychiatric Hospital from July 2009 to December 2009 were examined. All data were collected thru a chart review using a form that was created to systematically document experiences. A total of 229 patients were included in the study. There were no significant differences between treatment groups on gender, age, race or diagnosis. In the entire samples 1.75% had pseudo-parkonisnism, 1.31% had acute dystonia, 0.04% had tardive dyskinesia, 1.31% akithesia, and 4.8% any neurological side effects. There were no significant differences between agents in the likelihood of any of these side effects or of having any side effect. Higher use of anticholinergics was found in patients treated with FGAs. We also found that 77% were discharged on the same antipsychotic agent they received when they were initially hospitalized. A wide range of acute oral pharmacoptherapy in non-tablet formulations of first and SGAs should be available in psychiatric hospital formularies. FGAs seems to be as well tolerated as SGAs.
authors.affiliation: Department of Psychiatry, Yale University, School of Medicine, 300 George St, Suite 901, New Haven, CT 06511, USA. pascale.chrisphonte@yale.edu
authors.forename: Pascale
authors.initials: P
authors.lastname: Chrisphonte
authors.forename: Robert B
authors.initials: RB
authors.lastname: Ostroff
authors.forename: Robert A
authors.initials: RA
authors.lastname: Rosenheck
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004339:Drug Compounding; D016503:Drug Delivery Systems; D005260:Female; D005476:Fluphenazine / Q000008:administration & dosage / Q000009:adverse effects; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects; D006778:Hospitals, Psychiatric; D006801:Humans; D008297:Male; D009069:Movement Disorders / Q000453:epidemiology* / Q000209:etiology; D000077152:Olanzapine; D010351:Patient Discharge; D010546:Perphenazine / Q000008:administration & dosage* / Q000009:adverse effects; D018967:Risperidone / Q000008:administration & dosage / Q000009:adverse effects; D013535:Suspensions; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D018680:Cholinergic Antagonists; D013535:Suspensions; D001569:Benzodiazepines; D010546:Perphenazine; D006220:Haloperidol; D018967:Risperidone; D000077152:Olanzapine; D005476:Fluphenazine